PDC*line Pharma Company
PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells.
.png)
Estimated Revenue:
$1M to $10M
Funding Status:
Early Stage Venture
Industry:
Tumor-Specific Antigens, Whole-Cell Antigens
Investors Number:
10
Last Funding Date:
2021-12-06
Founded Date:
2014-04-01
Headquarters:
La Tronche, Rhone-Alpes, France
Total Funding:
46226696
Last Funding Type:
Series B
Employee Number:
1-10